-
Product Insights
NewNet Present Value Model: Gritstone Bio Inc’s GRANITE-001
Empower your strategies with our Net Present Value Model: Gritstone Bio Inc's GRANITE-001 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Gritstone Bio Inc’s SLATE-001
Empower your strategies with our Net Present Value Model: Gritstone Bio Inc's SLATE-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Pancreatic Ductal Adenocarcinoma Drug Details: SLATE-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Non-Small Cell Lung Cancer Drug Details: SLATE-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Colorectal Cancer Drug Details: SLATE-001 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Danvilostomig in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danvilostomig in Oral Cavity (Mouth) Cancer Drug Details: Danvilostomig (SIB-003)...
-
Product Insights
Human Papillomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus Infections - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Drugs In Development, 2023’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewNet Present Value Model: Harpoon Therapeutics Inc’s HPN-536
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QBS-10072S in Urinary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. QBS-10072S in Urinary Tract Cancer Drug Details: QBS-10072S is under development for the treatment of...